Samsung Biologics, LegoChem team up to develop new targeted cancer drugs
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"Samsung Biologics aims to enhance collaboration with promising domestic biotech companies such as LegoChem Biosciences to bolster technological competitiveness."
"Previously, we secured antibodies for ADCs solely through overseas companies," said LegoChem Biosciences CEO Kim Yong-zu. "With this agreement, we expect to establish a stable domestic supply chain with Samsung Biologics."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Samsung Biologics, South Korea's largest contract development and manufacturing organization, said Wednesday that it has signed a contract with LegoChem Biosciences to develop antibody-drug conjugate -- or simply ADC -- therapeutics, designed as targeted treatment for cancer.
LegoChem Biosciences, founded in 2006, specializes in research and development capabilities in therapeutics, especially with a focus on ADC technology and synthetic drugs.
Last year, LegoChem transferred its ADC drug candidate, LCB84, designed to treat solid tumors, to Janssen Biotech, a subsidiary of Johnson & Johnson, for 2.24 trillion won ($1.7 billion).
Under the agreement, Samsung Biologics will be responsible for the development of antibodies, which are essential for the development of ADCs, including cell line development and sample cell manufacturing for preclinical and clinical trials.
“We will continue to invest in the ADC field to secure competitiveness in the market as it is emerging as a next-generation biotechnology,” said Samsung Biologics CEO John Lim.
“Samsung Biologics aims to enhance collaboration with promising domestic biotech companies such as LegoChem Biosciences to bolster technological competitiveness."
"Previously, we secured antibodies for ADCs solely through overseas companies," said LegoChem Biosciences CEO Kim Yong-zu. "With this agreement, we expect to establish a stable domestic supply chain with Samsung Biologics."
Therapeutics companies with ADC technology -- in which Samsung Biologics has invested through the Samsung Life Science Fund -- include Araris Biotech, a Swiss ADC technology developer, in April and domestic biotech company AimedBio in September.
Samsung Biologics also expects to complete the construction of a production facility dedicated to manufacturing ADC-relevant drugs by the year-end.
By Hwang Joo-young(flylikekite@heraldcorp.com)
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.